New Study Demonstrates Feasibility of Novel Mechan

Late-Breaking Presentation at Heart Rhythm 2018 Shows Potential for More Patients to Benefit from World's Smallest Pacemaker

DUBLIN and BOSTON - May 11, 2018 - Medtronic plc (NYSE: MDT ) today announced new clinical study results demonstrating that an investigational algorithm, utilizing the accelerometer signal in the Micra(TM) Transcatheter Pacing System (TPS) may restore AV synchrony, improving cardiac function in patients with sinus rhythm and atrioventricular (AV) block. The results from the MARVEL (Micra Atrial TRacking Using A Ventricular AccELerometer) feasibility study were presented today during a late-breaking session at Heart Rhythm 2018, the Heart Rhythm Society's 39th Annual Scientific Sessions, and simultaneously published in  Heart Rhythm .

"The results of MARVEL indicate that this novel mechanical sensor may allow more patients to benefit from a miniaturized leadless pacemaker," said Larry Chinitz, M.D., MARVEL study principal investigator and cardiac electrophysiologist and director of NYU Langone's Heart Rhythm Center in New York City. "Although single-chamber pacing in the ventricle is quite safe for these patients, the preferred option is to treat them with a wired pacemaker in two chambers to maintain synchrony and cardiac function. However, patients with these traditional pacemakers are at risk of experiencing complications related to the pocket and the leads, and leadless pacemakers remove these risks."

The MARVEL study evaluated 64 patients who already had a Micra TPS at 12 centers in nine countries. Investigators evaluated the ability for the Micra's accelerometer to monitor and detect contractions in the atrium, even though the device is implanted in the ventricle. Investigators also evaluated Micra's ability to pace the ventricle to contract in sequence with the atrium, creating AV synchrony. AV synchrony was measured using continuous device telemetry and an electrocardiogram via a Holter monitor.

The study showed the percentage of AV beats in synchrony during pacing with the AV algorithm was 87 percent among all study patients (while they were at rest for 30 minutes), 80 percent in high-degree AV block patients, and 94.5 percent in patients with predominantly intact AV conduction during the study. In patients with high-degree AV block who would benefit the most from AV synchrony, the algorithm yielded significantly greater AV synchrony (P<0.001) compared to VVI pacing without the algorithm. In addition, AV block patients had a statistically significant improvement (P=0.004) in stroke volume (blood flow out of the left ventricle) during AV algorithm pacing (23.9cm LVOT VTI) compared to VVI pacing (21.8cm).

"We are encouraged by the results of MARVEL, which support our commitment to extending the benefits of Micra TPS to broader patient groups," said Rob Kowal, M.D., Ph.D., vice president and chief medical officer of the Cardiac Rhythm and Heart Failure division, which is part of the Cardiac and Vascular Group at Medtronic. "We are investing in additional clinical studies to confirm this accelerometer-based leadless pacing approach will benefit patients with AV block who make up approximately 40 percent of the pacemaker population worldwide."

Medtronic first introduced the Medtronic Micra TPS commercially in Europe in 2015 and in the United States in 2016 for patients who need a single-chamber pacemaker. Comparable in size to a large vitamin, the Micra TPS is less than one-tenth the size of traditional pacemakers, yet it delivers the most advanced pacing technology to patients via a minimally invasive approach. During the implant procedure, it is attached to the heart with small tines and delivers electrical impulses that pace the heart through an electrode at the end of the device.

Unlike traditional pacemakers, the Micra TPS does not require leads or a surgical "pocket" under the skin, so potential sources of complications related to such leads and pocket are eliminated - as are any visible signs of the device. Micra TPS utilizes a miniaturized sensor inside the device to measure patient movement (also known as an accelerometer) and determines appropriate pacing rates based on patient activity levels. 

Earlier results presented at HRS 2018 from the Micra Post-Approval Registry demonstrated major complications with Micra TPS were infrequent with a 63 percent lower risk for major complication ( P <0.001) compared to traditional pacing systems.

In collaboration with leading clinicians, researchers, and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services of the highest quality that deliver clinical and economic value to healthcare consumers and providers around the world.

About Medtronic Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 84,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange  Commission. Actual results may differ materially from anticipated results.

-end-

Contacts: Ryan Mathre Public Relations +1-651-335-2338 Ryan Weispfenning Investor Relations +1-763-505-4626